// App-Quantinova.ai

CTIM-08 : SAFETY, EFFICACY, AND SURVIVAL RESULTS FROM A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 FOLLOWED BY STANDARD OF CARE RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Researchers

Presenter

  • Jaime Gallego Perez-Larraya

Principal Investigators

  • Marc Garcia-Moure

  • Ana Patino-Garcia

  • Marisol Gonzalez-Huarriz

  • Jasper Van der Lugt

  • Itziar Astigarraga

  • Miguel García-Ariza

  • Blanca López-Ibor

  • Chris Jones

  • Alan Mackay

  • Ricardo Diez-Valle

  • Juan Fueyo

  • Candelaria Gomez-Manzano

  • Jessica Dobbs

  • Brett Ewald

  • Marta Alonso

  • Sonia Tejada

Medical Centers

  • DNAtrix, Houston, TX, USA

  • Health Research Institute of Navarra (IdiSNA), Pamplona, Pamplona, Navarra, Spain

  • Hospital HM Monteprincipe, Boadilla del Monte, Spain

  • Hospital Universitario Cruces, Barakaldo, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • MD Anderson Cancer Center, Houston, Texas, USA

  • Institute of Cancer Research, London, United Kingdom

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

Locations

  • United States

  • United Kingdom

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse intrinsic pontine glioma

Biomarkers

  • N/A

Drug/Treatment

  • Delta-24-RGD-4C

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved